All In Biotech

Drug Trial Radar · NCT03571256

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

158

Actual

Start

May 31, 2018

Primary completion

Dec 9, 2019

Study completion Dec 9, 2019

Sponsor

Sponsor type
Industry
Collaborators
Nuvelution TS Pharma, Inc.
First posted
Jun 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Standard placebo-controlled, double-blind study design (TEV-50717 \[low dose and high dose\] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS.

Conditions

  • Tourette Syndrome

Interventions

  • TEV-50717Drug

    6-, 9-, 12-, 15-, and 18 mg oral tablets

  • PlaceboDrug

    Placebo matched to TEV-50717 tablets will be taken BID.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated ParticipantsTime frame: Baseline, Week 8

Locations

56 sites in 10 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 060-0160

    Gainesville, Florida

  • Teva Investigational Site 060-0166

    Gulf Breeze, Florida

  • Teva Investigational Site 060-0161

    Miami, Florida

  • Teva Investigational Site 060-0151

    Orlando, Florida

  • Teva Investigational Site 060-0153

    Orlando, Florida

  • Teva Investigational Site 060-0168

    Atlanta, Georgia

  • Teva Investigational Site 060-0155

    Chicago, Illinois

  • Teva Investigational Site 060-0164

    Chicago, Illinois

  • Teva Investigational Site 060-0152

    Indianapolis, Indiana

  • Teva Investigational Site 060-0158

    Louisville, Kentucky

  • Teva Investigational Site 060-0167

    Rockville, Maryland

  • Teva Investigational Site 060-0165

    Ann Arbor, Michigan

  • Teva Investigational Site 060-0170

    Bridgeton, Missouri

  • Teva Investigational Site 060-0154

    New York, New York

  • Teva Investigational Site 060-0169

    Charleston, South Carolina

  • Teva Investigational Site 060-0157

    Memphis, Tennessee

  • Teva Investigational Site 060-0156

    Nashville, Tennessee

  • Teva Investigational Site 060-0163

    Fort Worth, Texas

  • Teva Investigational Site 060-0162

    Everett, Washington

  • Teva Investigational Site 060-1407

    Buenos Aires, Argentina

  • Teva Investigational Site 060-1401

    Buenos Aires, Argentina

  • Teva Investigational Site 060-1402

    Buenos Aires, Argentina

  • Teva Investigational Site 060-1403

    La Plata, Argentina

  • Teva Investigational Site 060-1404

    Mendoza, Argentina

  • Teva Investigational Site 060-1802

    Liverpool, Australia

  • Teva Investigational Site 060-1801

    Parkville, Australia

  • Teva Investigational Site 060-1503

    Bello, Colombia

  • Teva Investigational Site 060-1501

    Medellín, Colombia

  • Teva Investigational Site 060-1506

    Medellín, Colombia

  • Teva Investigational Site 060-1504

    Pereira, Colombia

  • Teva Investigational Site 060-0901

    Budapest, Hungary

  • Teva Investigational Site 060-0902

    Szeged, Hungary

  • Teva Investigational Site 060-1005

    Cagliari, Italy

  • Teva Investigational Site 060-1001

    Catania, Italy

  • Teva Investigational Site 060-1003

    Naples, Italy

  • Teva Investigational Site 060-1004

    Rome, Italy

  • Teva Investigational Site 060-1601

    Culiacán, Mexico

  • Teva Investigational Site 060-1603

    León, Mexico

  • Teva Investigational Site 060-1602

    Monterrey, Mexico

  • Teva Investigational Site 060-1604

    Monterrey, Mexico

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.